Abstract
The enantiomers of a series of dopamine (DA) agonists, monohydroxy-2-aminotetralin derivatives, were investigated using brain microdialysis. We used a 5-OH-substituted derivative, N-0437 (2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin), and three 7-OH-substituted derivatives, N-0438 (2-(N-propyl-N-2-thienylethylamino)-7-hydroxytetralin), 7-OH-DPAT (7-hydroxy-2-(N, N-di-n-propylamino)tetralin) and PHNO (4-propyl-9-hydroxynaphthoxazine; position 9 of the naphtoxazines corresponds to position 7 of the aminotetralins). We studied the activity of the enantiomers at autoreceptors regulating the release of DA following their local infusion into the striatum of the rat. We were particularly interested in the activity of R( + )-N-0437, S( - )-N-0438, S( − )-7-OH-DPAT and S( - )-PHNO, which are enantiomers that have been classified as less potent or inactive in previous studies. S(−)-N-0437, R( + )-N-0438, R( + )-7-OH-DPAT and R( + )-PHNO decreased DA release by 45–60%. Thus, these enantiomers are potent agonists at autoreceptors regulating the release of DA. The R( + ) enantiomer of the 5-OH-substituted derivative N-0437 possessed antagonistic activity at autoreceptors controlling DA release, increasing DA release by 100%. This finding is consistent with reports showing that one enantiomer of other 5-OH DA agonists displays agonistic activity, while the other has antagonistic properties at DA autoreceptors. The less potent enantiomers of the 7-OH-substituted derivatives S(−)-N-0438, S( − )-7-OH-DPAT and S(−)-PHNO, however, all showed weak agonistic activity at DA autoreceptors. They decreased DA release by maximally 40%. Thus, considering these results and the findings from the literature, the position of the hydroxyl group may determine the action profile of the enantiomers. Apparently, not only the R( + ) configuration but also the S(−) configuration of the 7-OH-substituted derivatives can bind and activate the autoreceptor regulating DA release, whereas only the S( − ) configuration of 5-OH-substituted derivatives is capable of doing so.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.